(Q45299715)

11 December 2017

title

Donepezil for Huntington's disease (English)

1 reference

11 December 2017

0 references

Fernandez HH

1

1 reference

11 December 2017

Friedman JH

series ordinal

2

1 reference

11 December 2017

Grace J

series ordinal

3

1 reference

11 December 2017

Beason-Hazen S

series ordinal

4

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

11 December 2017

1 reference

11 December 2017

volume

15

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

173-176

1 reference

Gilles de la tourette's syndrome in twins: Clinical and neurochemical data

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Trial of d-alpha-tocopherol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Huntington'S disease: Treatment with muscimol, A GABA-mimetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Treatment of Huntington disease with a cholinergic agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Huntington's disease: Clinical and chemical effects of choline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Deanol Acetamidobenzoate Treatment in Choreiform Movement Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

Dementia with Lewy bodies: response of delirium-like features to donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200001%2915%3A1%3C173%3A%3AAID-MDS1032%3E3.0.CO%3B2-T

10.1002/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference